Moleculin Biotech Stock Analysis

Moleculin Stock Analysis Notes

About 15.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.1. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Moleculin Biotech recorded a loss per share of 12.04. The entity last dividend was issued on the 1st of February 2021. The firm had 1:15 split on the 22nd of March 2024. Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. To find out more about Moleculin Biotech contact the company at (713) 300-5160 or learn more at https://moleculin.com.

Moleculin Biotech Investment Alerts

Moleculin Biotech Upcoming and Recent Events

Moleculin Largest EPS Surprises

View All Earnings Estimates

Moleculin Biotech Environmental, Social, and Governance (ESG) Scores

Moleculin Stock Institutional Investors

Note, although Moleculin Biotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Moleculin Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.2 M.

Moleculin Profitablity

Management Efficiency

Moleculin Biotech has return on total asset (ROA) of (0.5745) % which means that it has lost $0.5745 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4149) %, meaning that it created substantial loss on money invested by shareholders. Moleculin Biotech's management efficiency ratios could be used to measure how well Moleculin Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.15 in 2024. Return On Capital Employed is likely to drop to -0.99 in 2024. At this time, Moleculin Biotech's Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2.8 M in 2024, whereas Total Assets are likely to drop slightly above 35.4 M in 2024.

Technical Drivers

As of the 23rd of November, Moleculin Biotech secures the Downside Deviation of 4.64, risk adjusted performance of 0.054, and Mean Deviation of 3.8. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Moleculin Biotech, as well as the relationship between them.

Moleculin Biotech Price Movement Analysis

Moleculin Biotech Insider Trading Activities

Moleculin Biotech Outstanding Bonds

Moleculin Biotech Predictive Daily Indicators

Moleculin Biotech Corporate Filings

Moleculin Biotech Forecast Models

Moleculin Biotech's time-series forecasting models are one of many Moleculin Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Moleculin Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Moleculin Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Moleculin shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Moleculin Biotech. By using and applying Moleculin Stock analysis, traders can create a robust methodology for identifying Moleculin entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Moleculin analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Moleculin analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Moleculin Biotech stock analysis indicators help investors evaluate how Moleculin Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Moleculin Biotech shares will generate the highest return on investment. By understating and applying Moleculin Biotech stock analysis, traders can identify Moleculin Biotech position entry and exit signals to maximize returns.

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.